B
Bull
Bull · 25%NRSN
$2.41
Precio del escenario
$0.420
-0.007 (-1.55%)Al cierre
Loading chart…
- High
- 0.450
- Open
- 0.433
- VWAP
- 0.43
- Vol
- 80.10K
- Mkt Cap
- 18.40M
- Low
- 0.410
- Amount
- 34.17K
- EV/EBITDA, TTM
- 0.00
NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage pharmaceutical company engaged in the development of therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The Company’s lead product candidate, PrimeC, is an oral fixed-dose combination therapy designed for the treatment of ALS. In addition to PrimeC, the Company conducts research and development activities focused on neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease. The Company develops pharmaceutical products and therapeutic solutions aimed at addressing unmet medical needs in neurological diseases and related central nervous system disorders. The Company also advances therapies for rare neurological conditions.
AI analysis of Neurosense Therapeutics Ltd (NRSN)
holdNeurosense Therapeutics Ltd is currently not a strong buy due to its ongoing financial losses and compliance risks, despite some positive catalysts. The current price is $0.42, which is significantly below the analyst's target of $3, indicating potential upside. However, the company reported a net income loss of $2.15 million for Q3 2024, and it faces a Nasdaq compliance warning for trading below $1.00, which poses a risk to its listing status.
Métricas de valoración
The current forward P/E ratio for Neurosense Therapeutics Ltd (NRSN) is 0.00, compared to its 5-year average forward P/E of -2.10.
Alphio AI Price Scenarios for NRSN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
8.508-31PRnewswireNeuroSense Redesigns PrimeC Development Plan for ALS
8.508-13PRnewswireNeuroSense Initiates PARAGON Study, Focusing on ALS Treatment
8.508-06PRnewswireNeuroSense Targets December 2026 for ALS New Drug Submission
8.507-22PRnewswireNeuroSense Plans New Drug Submission to Health Canada for ALS Treatment
8.507-06PRnewswireNeuroSense Participates in ALS Expert Webinar
NRSN FAQ — answered by Alphio AI
NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage pharmaceutical company engaged in the development of therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The Company’s lead product candidate, PrimeC, is an oral fixed-dose combination therapy designed for the treatment of ALS. In addition to PrimeC, the Company conducts research and development activities focused on neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease. The Company develops pharmaceutical products and therapeutic solutions aimed at addressing unmet medical needs in neurological diseases and related central nervous system disorders. The Company also advances therapies for rare neurological conditions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Neurosense Therapeutics Ltd is currently not a strong buy due to its ongoing financial losses and compliance risks, despite some positive catalysts. The current price is $0.42, which is significantly below the analyst's target of $3, indicating potential upside. However, the company reported a net income loss of $2.15 million for Q3 2024, and it faces a Nasdaq compliance warning for trading below $1.00, which poses a risk to its listing status.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.